Evidence map›Paper›PMID 41931019›Full record

ReviewRadiology. Imaging cancer2026

A Framework for MRI Characterization of Intracranial Metastatic Disease.

Arian Lasocki, Stefanie Catherine Thust, Grant A McArthur

Abstract readReview
In one paragraph

Review in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arian LasockiDepartment of Cancer Imaging, Peter MacCallum Cancer Centre, Grattan St, Melbourne, Victoria 3000, Australia.ORCID 0000-0001-8176-3015
Stefanie Catherine ThustPrecision Imaging, School of Medicine, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0001-5136-6000
Grant A McArthurSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-8908-6071

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracranial metastases (IM) are far more common than primary malignant brain tumors, yet remain understudied, representing an important unmet clinical need. Although patients with IM have historically been excluded from clinical trials, thus limiting assessment of intracranial treatment efficacy, their inclusion is increasing; however, patients with suspected leptomeningeal metastatic disease (LMD) remain commonly excluded, likely due to poorer prognosis and anticipated limited treatment response. Despite established treatment response criteria for confirmed LMD, there is limited guidance on how LMD should be diagnosed or excluded in broader IM trials, creating substantial risk for variability and misclassification. This article addresses the gap by proposing MRI-based criteria for classifying IM appearances with respect to LMD suspicion, focusing on the exclusion of LMD, illustrated with real patient examples. IM-related MRI findings are categorized into three groups:

Indexed as

Brain NeoplasmsMagnetic Resonance ImagingMeningeal NeoplasmsDiagnosis, DifferentialHumansIntracranial MetastasisLeptomeningeal Metastatic DiseaseMRI

Identifiers

PMID41931019
PMCPMC13231196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.